logo.png
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
November 11, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
logo.png
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
May 28, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
logo.png
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
logo.png
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
March 07, 2019 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
logo.png
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
March 04, 2019 09:15 ET | Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
logo.png
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
January 03, 2019 10:01 ET | Corbus Pharmaceuticals Holdings, Inc.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances strategy to partner...
CRBP-300-196.png
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
August 08, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and JapanRecent long-term...